Neoton powder for solution for inf. 1000mg vial 4 pcs


Neoton powder for solution for inf. 1000mg vial 4 pcs



Active substance:
1 vial contains: sodium phosphocreatine tetrahydrate, 1 g
White powder in the form of granules.
Product form:
powder for solution for infusion of 1 g: 1 g of powder in a vial from a neutral colorless glass type II with a rubber stopper and an aluminum cap with a break-lid coming off.
4 vials together with instructions for use in a cardboard package.
Hypersensitivity to the drug; chronic renal failure (when using the drug in doses of 5 – 10 g / day); age 18 years (effectiveness and safety have been established).
1000 mg
Neoton used in a combination therapy of the following diseases:
acute myocardial infarction; chronic heart failure;
intraoperative myocardial ischemia;
intraoperative ischemia of the lower limbs,
in sports medicine for the prevention of the development of the syndrome of acute and chronic physical stress and improve athletes adapt to extreme physical stress.
Interaction with other drugs
When used in combination therapy Neoton drug enhances the effectiveness of antiarrhythmic, antianginal agents and agents with positive inotropic action. Neoton is stable in water for injection, a solution of 5% dextrose (glucose), and in cardioplegic solutions.
Currently, the cases of drug overdose Neoton were reported.
pharmachologic effect
Pharmacological group:
Metabolic means.
Phosphocreatine play an important role in the energy mechanism of muscle contraction. It is a reserve of energy in the cells of myocardium and skeletal muscle, and used for re-synthesis of adenosine triphosphate (ATP), which is released during the hydrolysis energy for the process of reducing actomyosin. Insufficient energy intake into cardiomyocytes associated with slowing the oxidative processes – a key mechanism for the development and progression of myocardial damage. Lack of phosphocreatine leads to a decrease in myocardial contractile force and its ability to functional recovery. When myocardial injury there was a close correlation between the amount of high energy phosphorylated compounds in cells, cell viability and their ability to restore motility. Preclinical and clinical studies have demonstrated cardioprotective influence of phosphocreatine, which is manifested in a dose-dependent positive effect in the toxic effects on the myocardium isoprenaline, thyroxine, emetine, p-nitrophenol; in the positive inotropic effect when glucose deficiency, calcium ions or potassium ions in overdose; in the reduction of negative inotropic effects due to anoxia. Furthermore, addition of phosphocreatine in the cardioplegic solutions in a concentration of 10 mmol / l improves the cardioprotective effects: decreases the risk of myocardial ischemia during cardiopulmonary bypass surgery; • decreasing the risk of developing reperfusion arrhythmias when administered prior to infusion of experimental regional ischemia resulting ligation overlay anterior descending branch of the left coronary artery for 15 min; reduces degradation of ATP and phosphocreatine in myocardial cells, retains the structure of the mitochondria and the sarcolemma, improves the functional recovery of the myocardium following cardiac arrest caused by the introduction of large doses of potassium, and reduces the incidence of reperfusion arrhythmia.
Phosphocreatine has cardioprotective action in an experiment in myocardial infarction and arrhythmia caused by coronary artery occlusion saves cellular pool of adenine nucleotides by inhibiting the enzymes responsible for their catabolism inhibits degradation of the phospholipids may improve microcirculation in the area of ​​ischemia, which is caused by the suppression mediated by adenosine aggregation acid platelets, to stabilize the hemodynamic parameters, prevent a sharp decline in functional parameters serd a, has antiarrhythmic effect, reduces the incidence and duration of ventricular fibrillation and myocardial infarction limits zone.
Distribution: after a single intravenous infusion phosphocreatine maximum concentration in plasma is determined by 1-3 min. The greatest amount of phosphocreatine stored in the skeletal muscles, myocardium and brain. In the tissues of the liver and the lungs accumulation of phosphocreatine insignificant.
Excretion: Excretion phosphocreatine biphasic ( “fast” and “slow” phase) due to its accumulation during the second phase in the tissues, followed by excretion from the body. The half-life in the “fast” phase is 30-35 minutes; half-life in the “slow” phase of several hours. Excreted by the kidneys.
Pregnancy and breast-feeding
Clinical data on the use during pregnancy Neoton not. However, studies in animals have shown the toxic effect of the drug on fertility in rats and rabbits embriofetalnoe development. Neoton can be used during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus. If necessary, use during lactation, breast-feeding should be discontinued.
Conditions of supply of pharmacies
On prescription.
side effects
Increased sensitivity to the drug, decrease in blood pressure (during rapid intravenous administration).
special instructions
The drug should be administered as soon as possible since the introduction of ischemia symptoms, which provides a more favorable prognosis. Use of the drug Neoton in high doses (5-10 g / d) is accompanied by an increased capture of phosphates in the kidney, which affects the exchange of calcium, secretion of hormones that regulate homeostasis, renal function and exchange purines therefore not recommended for prolonged use of the drug Neoton at high doses.
Storage conditions
Store at a temperature not higher than 30 ° C.
Keep out of the reach of children.
Dosing and Administration
Only intravenously (drip or as a fast infusion)
Acute myocardial infarction:
1 day: 2-4 g of the drug, dissolved in 50 ml of water for injection, in the form of on / in rapid infusion followed / in infusion of 8-16 g per 200 ml of 5% dextrose (glucose) for 2 hours.
Day 2: 2-4 g in 50 ml water for injection / drip (infusion duration not less than 30 minutes), 2 times / day.
Day 3: 2 g in 50 ml water for injection / drip (infusion duration not less than 30 minutes), 2 times / day.
If desired rate of infusion of 2 g of 2 times / day. It can be carried out within 6 days.
Chronic heart failure.
Depending on the condition of the patient can start treatment “shock” doses of 5-10 g in 200 mL of 5% dextrose (glucose) / drip at a rate of 4-5 g / hr for 3-5 days and then go on / in the drip (infusion duration not less than 30 min) 1-2 g of the drug, dissolved in 50 ml of water for injection, 2 times / day. for 2-6 weeks or once a start / drip in maintenance doses Neoton preparation (within 2-6 weeks of 1-2 g in 50 ml water for injection 2 times / day.).
Intraoperative myocardial ischemia.
Recommended Course / drip infusion for at least 30 minutes to 2 g in 50 ml water for injection 2 times / day. for 3-5 days prior to surgery and for 1-2 days thereafter. During surgery Neoton drug added in the usual cardioplegic solution in a concentration of 10 mmol / l or 2.5 g / L just prior to administration.
Intraoperative ischemia of the lower limbs.
Neoton 2-4 g of the drug in 50 ml of water for injection in the form of on / in rapid infusion prior to surgery followed by / in the drip of 8.10 g in 200 ml of 5% dextrose (glucose) at a rate of 4-5 g / h during surgery and during reperfusion.
In sports medicine for the prophylaxis of acute and chronic physical overexertion syndrome and improve the adaptation of athletes to extreme physical stresses preparation Neoton should be applied at a dose of 1 g / day in 50 ml of water for injection / drip (duration of infusion for at least 30 minutes) for 3-4 weeks.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review